13F Holdings
中文EN

GTHP GUIDED THERAPEUTICS INC

Electromedical & Electrotherapeutic Apparatus · OTC · SEC CIK 924515 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY283.1%
TTM net income YoY-15.6%
TTM EPS YoY40.0%
Revenue 3-yr CAGR117.8%
Net income 3-yr CAGR—

Margins

Gross margin80.4%
Operating margin-304.0%
Net margin-446.2%
FCF margin—
EBITDA margin-302.5%

Returns

ROE—
ROA-267.0%
ROIC (approx.)—
Asset turnover0.60x

Leverage & solvency

Liabilities / assets546.1%
Debt / equity—
Current ratio0.11x
Interest coverage-3.31x

Cash quality & payout

Operating cash flow / net income0.52x
Accruals ratio-128.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$767,000$7,000$98,000$13,000$81,000
Cost of revenue$196,000$5,000$62,000$81,000$61,000
Gross profit$571,000$2,000$36,000-$68,000$20,000
R&D expense$469,000$526,000$228,000$77,000$69,000
SG&A expense$2.31M$1.30M$3.00M$3.01M$2.17M
Operating income-$2.37M-$2.11M-$3.46M-$3.33M-$2.36M
Interest expense$617,000$381,000$278,000$582,000$1.15M
Pretax income-$3.20M-$2.42M-$3.49M-$4.34M-$2.07M
Income tax$0$0$0$0$0
Net income-$3.20M-$2.42M-$3.49M-$4.34M-$2.07M
EBITDA-$2.36M-$2.10M-$3.45M-$3.33M-$2.36M
EPS (basic)-0.04-0.05-0.07-0.15-0.18
EPS (diluted)-0.04-0.05-0.07-0.15-0.18
Weighted avg. shares (diluted)78.41M57.34M51.13M32.51M13.38M
Balance sheet
Cash & equivalents$63,000$388,000$591,000$2.31M$643,000
Receivables$4,000$3,000$7,000$6,000$46,000
Inventory$448,000$633,000$632,000$548,000$571,000
Current assets$605,000$1.20M$1.39M$3.00M$1.64M
PP&E, net$16,000$23,000$32,000$42,000$14,000
Total assets$1.32M$1.38M$1.67M$3.37M$2.04M
Current liabilities$6.64M$6.16M$4.81M$4.87M$5.69M
Short-term debt——$0$17,000$88,000
Long-term debt———$0$22,000
Total debt———$17,000$110,000
Total liabilities$7.33M$6.27M$5.47M$6.25M$7.49M
Shareholders' equity-$6.01M-$4.89M-$3.81M-$2.88M-$5.45M
Net debt———-$2.30M-$533,000
Shares outstanding86,15465.13M54.10M48.60M13.67M
Cash flow statement
Operating cash flow-$1.07M-$1.12M-$1.75M-$1.48M-$1.59M
Capital expenditure$2,000$0$0$31,000$14,000
Free cash flow-$1.07M-$1.12M-$1.75M-$1.51M-$1.61M
Investing cash flow-$2,000$0—-$31,000-$14,000
Financing cash flow$745,000$916,000$24,000$3.18M$2.07M
Depreciation & amortization$10,000$9,000$9,000$4,000$1,000
Stock-based compensation$377,000$120,000$1.81M$1.38M$228,000

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.